Role of melatonin in cancer treatment

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2747-2754

  Cutando, Antonio ^a   López Valverde, Antonio ^b   Arias Santiago, Salvador ^c   De Vicente, Joaquin ^b   De Diego, Rafael Gómez ^d  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d UNIVERSIDAD ALFONSO X EL SABIO   (Spain)

Author keywords

Cancer; Immune mechanisms; Melatonin; Melatonin receptors; Review

Indexed keywords

ANTINEOPLASTIC AGENT; CALMODULIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 50; INTERLEUKIN 2; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TAMOXIFEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; DISEASE ASSOCIATION; ENZYME INDUCTION; ESTROGEN RESPONSIVE ELEMENT; HORMONE ACTION; HORMONE INHIBITION; HORMONE PROTEIN COMPLEX; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC);

AGE FACTORS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; HUMANS; MELATONIN; NEOPLASMS;

EID: 84865696632     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Reiter P: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12: 151-180, 1991.
2. Vijayalaxmi, Thomas CR Jr., Reiter RJ and Herman TS: Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20: 2575-2601, 2002.
3. Pandi-Perumal SR, Zisapel N, Srinivasan V and Cardinali DP: Melatonin and sleep in aging population. Exp Gerontol 40: 911-925, 2005. (Pubitemid 41683162)
4. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM and Reiter RJ: Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34: 75-78, 2003.
5. Hardeland R, Tan DX and Reiter RJ: Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 47: 109-126, 2009.
6. Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S and Galli F: Melatonin signaling and cell protection function. FASEB J 24: 3603-3624, 2010.
7. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I and Cardinali DP: Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 7: 189-203, 2008.
8. Dubocovich ML and Markowska M: Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 27: 101-110, 2005. (Pubitemid 41558442)
9. Jung B and Ahmad N: Melatonin in cancer management: progress and promise. Cancer Res 66: 9789-9793, 2006. (Pubitemid 44672026)
10. Dubocovich ML, Cardinali DP, Guardiola-Lemaitre RM, Hagan RM, Krause DN, Sugden D et al: Melatonin receptiors. In: Girdlestone D (ed.). The IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR Media: London, pp. 187-193, 1998.
11. Reppert SM: Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 12: 528-531, 1997.
12. Ivanova EA, Bechtold DA, Dupré SM, Brennand J, Barrett P, Luckman SM and Loudon AS: Altered metabolism in the melatonin-related receptor (GPR50) knockout mouse. Am J Physiol Endocrinol Metab 294: E176-E182, 2008.
13. Sidibe A, Mullier A, Chen P, Baroncini M, Boutin JA, Delagrange P, Prevot V and Jockers R: Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. J Pineal Res 48: 263-269, 2010.
14. Civelli O, Saito Y, Wang Z, Nothacker HP and Reinscheid RK. Orphan GPCRs and their ligands. Pharmacol Ther 110: 525-532, 2006.
15. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P and Jockers R: The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 25: 3012-3023, 2006. (Pubitemid 44106754)
16. Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H and Reiter RJ: Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 43: 317-320, 2007. (Pubitemid 47512273)
17. Mailliet F, Ferry G, Vella F, Berger S, Cogé F, Chomarat P, Mallet C, Guénin SP, Guillaumet G, Viaud-Massuard MC, Yous S, Delagrange P and Boutin JA: Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol 71: 74-88, 2005.
18. Mediavilla MD, Sánchez-Barceló EJ, Tan DX, Manchester L and Reiter RJ: Basic mechanisms envolved in the anti-cancer effects of melatonin. Curr Med Chem 36: 4462-4480, 2010.
19. Ravindra T, Lakshmi NK and Ahuja YR: Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci 60: 523-535, 2006. (Pubitemid 44935001)
20. Jung-Hynes B, Reiter RJ and Ahmad N: Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 48: 9-19, 2010.
21. Benítez-King G, Soto-Vega E and Ramírez-Rodriguez G: Melatonin modulates microfilament phenotypes in epithelial cells: implications for adhesion and inhibition of cancer cell migration. Histol Histopathol 24: 789-799, 2009.
22. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006.
23. Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP and Cardinali DP: Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 5: 109-23, 2011.
24. Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994.
25. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS and Ramos S: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868, 1999. (Pubitemid 29220698)
26. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S and Reiter RJ: Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60: 1407-1426, 2003. (Pubitemid 36900523)
27. Leon-Blanco MM, Guerrero JM, Reiter RJ, Calvo JR and Pozo D: Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 35: 204-211, 2003. (Pubitemid 37100399)
28. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res 48: 178-184, 2010.
29. Szczepanik M. Melatonin and its influence on immune system. J Physiol Pharmacol 58(Suppl 6): 115-124, 2007.
30. Mediavilla MD, Sánchez-Barceló EJ, Tan DX, Manchester L and Reiter RJ: Basic mechanisms envolved in the anti-cancer effects of melatonin. Curr Med Chem 36: 4462-4480, 2010.
31. Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170, 2000.
32. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T and Mao L: Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 8: 337-346, 2009.
33. Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10: 153-159, 2003.
34. Knower KC, To SQ, Takagi K, Miki Y, Sasano H, Simpson ER and Clyne CD: Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat 132: 765-771, 2012.
35. Treeck O, Haldar C and Ortmann O: Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 15: 231-235, 2006.
36. Farriol M, Venereo Y, Orta X, Castellanos JM and Segovia-Silvestre T: In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 20: 21-24, 2000. (Pubitemid 30093182)
37. Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T and Rahman KM: Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 177: 128-136, 2009.
38. Nemeth C, Humpeler S, Kallay E, Mesteri I, Svoboda M, Rögelsperger O, Klammer N, Thalhammer T and Ekmekcioglu C: Decreased expression of the melatonin receptor 1 in human colorectal carcinomas. J Biol Regul Homeost Agents 25: 531-542, 2011.
39. Winczyk K, Pawlikowski M, Lawnicka H, Kunert-Radek J, Spadoni G, Tarzia G and Karasek M: Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl] propanamide on murine Colon 38 cancer growth in vitro and in vivo. Neuro Endocrinol Lett 23(Suppl 1): 50-54, 2002. (Pubitemid 34495382)
40. Lin ZY and Chuang WL: Pharmacologic concentrations of melatonin have diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 64: 659-662, 2010.
41. Nishimura J, Saegusa Y, Dewa Y, Jin M, Kawai M, Kemmochi S, Harada T, Hayashi SM, Shibutani M and Mitsumori K: Antioxidant enzymatically modified isoquercitrin or melatonin supplementation reduces oxidative stress-mediated hepatocellular tumor promotion of oxfendazole in rats. Arch Toxicol 84: 143-153, 2010.
42. Cabrera J, Negrín G, Estévez F, Loro J, Reiter RJ and Quintana J: Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 49: 45-54, 2010.
43. Izykowska I, Gebarowska E, Cegielski M, Podhorska-Okolow M, Piotrowska A, Zabel M and Dziegiel P: Effect of melatonin on melanoma cells subjected to UVA and UVB radiation in in vitro studies. In Vivo 23: 733-738, 2009.
44. Kim BC, Shon BS, Ryoo YW, Kim SP and Lee KS: Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. J Dermatol Sci 26: 194-200, 2001.
45. Watanabe M, Kobayashi Y, Takahashi N, Kiguchi K and Ishizuka B: Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. J Obstet Gynaecol Res 34: 567-573, 2008.
46. Esposito E, Iacono A, Muià C, Crisafulli C, Mattace Raso G, Bramanti P, Meli R and Cuzzocrea S: Signal transduction pathways involved in protective effects of melatonin in C6 glioma cells. J Pineal Res 44: 78-87, 2008. (Pubitemid 350231099)
47. Min KJ, Kim HS, Park EJ and Kwon TK: Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen species-mediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells. J Pineal Res 2012, doi: 10.1111/j.1600-079X.2012.00975.x.
48. Koh W, Jeong SJ, Lee HJ, Ryu HG, Lee EO, Ahn KS, Bae H and Kim SH: Melatonin promotes puromycin-induced apoptosis with activation of caspase-3 and 5′-adenosine monophosphate-activated kinase-alpha in human leukemia HL-60 cells. J Pineal Res 50: 367-373, 2011.
49. Casado-Zapico S, Martín V, García-Santos G, Rodríguez-Blanco J, Sánchez-Sánchez AM, Luño E, Suárez C, García-Pedrero JM, Menendez ST, Antolín I and Rodriguez C: Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients. J Pineal Res 50: 345-355, 2011.
50. Tam CW and Shiu SY: Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res 51: 297-312, 2011.
51. Zhang S, Zuo L, Gui S, Zhou Q, Wei W and Wang Y: Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Res 39: 2843-2849, 2012.
52. Cutando A, Aneiros-Fernández J, Aneiros-Cachaza J and Arias-Santiago S: Melatonin and cancer: current knowledge and its application to oral cavity tumours. J Oral Pathol Med 40: 593-597, 2011.
53. Casado-Zapico S, Rodriguez-Blanco J, García-Santos G, Martín V, Sánchez-Sánchez AM, Antolín I and Rodriguez C: Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 48: 72-80, 2010.
54. Toma CD, Svoboda M, Arrich F, Ekmekcioglu C, Assadian O and Thalhammer T: Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res 43: 206-213, 2007. (Pubitemid 47077224)
55. Reiter RJ, Tan DX, Korkmaz A, Erren TC, Piekarski C, Tamura H and Manchester LC: Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 13: 303-328, 2007. (Pubitemid 351655045)
56. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I and Colditz GA: Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93: 1563-1568, 2001. (Pubitemid 32998486)
57. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS and Colditz GA: Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95: 825-828, 2003. (Pubitemid 36798430)
58. Megdal SP, Kroenke CH, Laden F, Pukkala E and Schernhammer ES: Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 41: 2023-2032, 2005. (Pubitemid 41557687)
59. International Agency for Research on Cancer. IARC Monographs Programme finds cancer hazards associated with shiftwork, painting and firefighting. Press release no. 180, 5 December 2007. http://www.iarc.fr/en/media-centre/pr/2007/ pr180.html
60. Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ, Dong TF and Fu QL: The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 2012, doi: 10.1007/s00280-012-1828-8.
61. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ and Mills E: Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther 2011, doi: 10.1177/1534735411425484.
62. Mills E, Wu P, Seely D and Guyatt G: Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39: 360-366, 2005.
63. Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S, Esposti D, Zubelewicz B and Braczowski R: A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. Oncol Rep 2: 871-873, 1995.
64. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F and Tancini G: A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 52: 243-245, 1995.
65. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G and Lissoni P: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 23: 1951-1954, 2003. (Pubitemid 36750873)
66. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G, Conti A and Maestroni GJM: Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 49: 336-339, 1992.
67. Ghielmini M, Pagani O, de Jong J, Pampallona S, Conti A, Maestroni G, Sessa C and Cavalli F: Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer 80: 1058-1061, 1999. (Pubitemid 29233929)
68. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G and Frigerio F: A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 80: 464-467, 1994.
69. Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A and Maestroni GJ: A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 23: 15-19, 1997. (Pubitemid 127500264)
70. Lissoni P, Chilelli M, Villa S, Cerizza L and Tancini G: Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35: 12-15, 2003. (Pubitemid 36819165)